Fig. 1

Expression of angiogenic mediators in tumor conditioned media from resected CRC tissue. The MSD V-plex Angiogenesis panel 1 was used to determine the expression level of 7 angiogenic markers in tumor conditioned media generated from resected patient CRC tissue (n = 8). a Treatment with 1,4-dihydroxy quininib or Bevacizumab alone was found to significantly decrease TIE-2 expression level (p < 0.05, FC = 1.2 and p < 0.01, FC = 1.7, respectively) and in combination with Bevacizumab (p < 0.01, FC = 2.7) or FOLFOX (p < 0.05, FC = 1.5) compared to control. b A significant reduction in VEGF expression was observed following treatment with Bevacizumab (p < 0.01, FC = 76.0) and 1,4-dihydroxy quininib combined with Bevacizumab (p < 0.01, FC = 58.2). c A significant reduction in VEGF-D expression was observed following treatment with Bevacizumab (p < 0.05, FC = 5.2), 1,4-dihydroxy quininib combined with Bevacizumab (p < 0.05, FC = 7.5) or FOLFOX (p < 0.05, FC = 2.7). Statistical analysis was performed using Wilcoxon signed rank test to determine significance between groups. (*p < 0.05, **p < 0.01). 1,4-dihydrox. Quin. = 1,4-dihydroxy quininib, Bev = Bevacizumab, FC = Fold Change. Error bars represent mean SEM. Non-significant results are found in Supplementary Figure 1